Shionogi Pharmaceutical Co., Ltd., headquartered in Osaka, announced that it has begun clinical trials of a new coronavirus vaccine under development in children aged 5 to 11 years.
Shionogi Pharmaceutical is already conducting clinical trials of a new type of coronavirus vaccine called "recombinant protein vaccine" under development for people aged 12 and over and those aged 18 and over.
According to the company, this clinical trial is targeted at 5 to 11 years old, and 48 participants will be vaccinated twice with the vaccine under development to confirm the safety when inoculating children.
The vaccine used is the same ingredient used in clinical trials for adults, this time to confirm the appropriate amount for children aged 5 to 11 years.
The company plans to apply for approval in the country while considering the results of clinical trials.
Shionogi said, "Vaccine options that can be inoculated between the ages of 5 and 11 are limited in Japan, and we would like to prepare multiple options for children who need the vaccine. Development of a vaccine that can be used by a wide range of age groups from children to the elderly. Aim for. "